The use of remdesivir outside of clinical trials during the COVID-19 pandemic
Abstract With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Journal of Pharmaceutical Policy and Practice |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40545-020-00258-8 |